PDC*line Pharma, a clinical-stage biotech company developing a new class of immunotherapies for cancers, presented the ...

近期来自浙江大学和腾讯AI Lab的研究团队在《自然-方法》发表了论文“人类CD8+ T细胞在炎症和癌症中的综合图谱”（Integrative mapping of human CD8+ T cells in inflammation and ...

而在配对的肿瘤组织样本中，也能找到与外周血中基因特征高度一致，但尚未因抗原慢性刺激进入耗竭状态的KIR+CD8+T细胞，它们可能会在肿瘤微环境内发挥免疫抑制作用。研究者们又基于患者肿瘤新抗原数据构建了肿瘤相关抗原肽库，通过TCR转导细胞系，证实KIR+CD8+T细胞存在肿瘤抗原特异性，即能够被来自肿瘤的抗原激活。

Therapeutics is pleased to showcase its survival and clinical benefit data in MBC patients, including those with CNS ...

Data from the ongoing Phase 2 of EO4010 demonstrate tumor target specific immune responses and objective tumor responses, including in liver mets, in patients with previously treated microsatellite ...

Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) ...

Therapeutic mRNAs offer great potential as a versatile and precise tool against cancer and other diseases. However, the ...

EnnoDC presents preliminary data for immunotherapy candidate CD40.HVac in HPV+ oropharyngeal cancer at ESMO IO 2024 ...

Yale researchers have made an unexpected discovery—turncoat T cells that help a tumor evade other cancer-fighting immune T ...

Opioids are often first-line treatments for cancer-related pain, but they can suppress the immune system and reduce the ...

Cancer cells impair monocyte-mediated T-cell activation by disrupting inflammatory pathways in the tumor microenvironment.